MNK News 88.95 09/23/2014 05:16:29 Mallinckrodt Plc Ordinary

New Post Public Reply Private Reply Replies (0) Message Board

Sep 23, 2014 at 6:16 AM

Mallinckrodt Plc Ordinary Share (MNK) 88.95 $MNK

Mallinckrodt (MNK) Highlighted As Momo Momentum Stock
at The Street - Fri Sep 19, 9:14AM CDT
Trade-Ideas LLC identified Mallinckrodt (MNK) as a momo momentum candidate

Impax Rytary FDA Action Date Extended by Three Months - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 3:30PM CDT
The FDA has pushed back the PDUFA date for Impax Laboratories, Inc.'s Rytary by three months to Jan 9, 2015.

Alcobra (ADHD) Worth Watching: Stock Moves 5.1% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 8:25AM CDT
Alcobra (ADHD) was a big mover last session, with shares rising over 5% on the day.

Novo Nordisk's Tresiba Effective in Children & Adolescents - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:10PM CDT
Novo Nordisk (NVO) announced new positive data from the BEGIN YOUNG 1 study on Tresiba for type I diabetes in children and adolescents (1 year to <18 years).

Earnings, Market Activity, Investment Agreements, Study Data, and Product Deployment - Research Reports on Darden, XPO, Mallinckrodt, SJM and Honeywell
PR Newswire - Wed Sep 17, 7:40AM CDT
Today, Analysts Review released its research reports regarding Darden Restaurants, Inc. (NYSE: DRI), XPO Logistics, Inc. (NYSE: XPO), Mallinckrodt PLC (NYSE: MNK), St. Jude Medical Inc. (NYSE: STJ) and Honeywell International Inc. (NYSE: HON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6529-100free.

NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 6:05PM CDT
The EMDAC of the FDA recommended the approval of NPS Pharmaceuticals' Natpara.

Can Mallinckrodt public limited (MNK) Keep the Earnings Streak Alive This Quarter? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 12, 7:54AM CDT
Mallinckrodt public limited could be a great candidate for another beat after a solid performance in the last two quarters.

Mylan to Acquire U.S. Rights to Arixtra for up to $300M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:20PM CDT
Mylan (MYL) is all set to acquire the U.S. commercialization, marketing and intellectual property rights to Arixtra injection from Aspen.

Actavis' Bystolic Combination Gets Negative FDA Panel Vote - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 3:45PM CDT
Actavis plc (ACT) announced that the FDA's CRDAC has voted against the approval (in the ratio of 6:4) of Actavis' fixed-dose combination (FDC) of Bystolic (nebivolol) and Novartis' (NVS) Diovan (valsartan).

Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
Maharathi Basu - Zacks Investment Research - Wed Sep 10, 3:30PM CDT
Emergent BioSolutions (EBS) secured a federal contract worth up to $29 million.

Endocyte (ECYT) Worth Watching: Stock Soars 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Sep 10, 8:46AM CDT
Endocyte (ECYT) was a big mover last session, with shares rising just over 17% on the day.

Actavis' Antibiotic under FDA Review, Response in 1Q15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 4:20PM CDT
Actavis plc (ACT) announced the acceptance of its new drug application for its antibiotic candidate, ceftazidime-avibactam, by the FDA.

Mallinckrodt (MNK) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:39AM CDT
Mallinckrodt (MNK) Shares March Higher, Can It Continue?

Technical Snapshot on Pharma Stocks - Allergan, Akorn, Mallinckrodt, Mylan, and AVANIR Pharma
PR Newswire - Mon Sep 08, 8:25AM CDT
On Friday, September 5, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average advanced 0.40%, to finish the day at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, with the index also advancing 6.70% in the last three months. Investor-Edge has initiated coverage on the following equities: Allergan Inc. (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Mallinckrodt PLC (NYSE: MNK), Mylan Inc. (NASDAQ: MYL), and AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR). Free research on these five companies can be accessed at:

IntelliPharmaCeutics (IPCI) in Focus: Stock Gains 15.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 8:25AM CDT
IntelliPharmaCeutics (IPCI) was a big mover last session, with shares rising nearly 16% on the day.

New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.

New REMS Education Program Helps Increase Safe, Responsible Use of Opioid Analgesics for Pain Relief
Business Wire - Mon Sep 08, 7:01AM CDT
Assessments of a novel Continuing Medical Education (CME) initiative showed meaningful changes in opioid prescribing behavior and improvements in pain-patient outcomes. These assessments of REMEDIES (Risk Evaluation and Mitigation Strategies - An Employer-Driven CME Initiative for Efficacy and Safety) - were presented this past week at PAINWeek, the nation's largest conference for clinicians with an interest in pain management.

Mallinckrodt's Pain Therapy Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:05PM CDT
Mallinckrodt plc (MNK) announced encouraging results from a phase III efficacy study on its pain candidate, MNK-155.

Mallinckrodt Pharmaceuticals Presents 11 Posters with Data on Investigational Opioid, MNK-155, and XARTEMIS(TM) XR (oxycodone hydrochloride and acetaminophen) Extended Release Tablets (CII) at PAINWeek 2014
Business Wire - Fri Sep 05, 8:00AM CDT
Mallinckrodt (NYSE: MNK) presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), at PAINWeek, September 2-6 in Las Vegas, Nevada. The studies examined the compound's efficacy, safety, abuse-related characteristics and release/delivery profiles with immediate- and extended-release components.

Actavis' Gastrointestinal Drug Under FDA Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 3:30PM CDT
Shares of Actavis plc (ACT) were up 0.9% after the company announced that the FDA has granted priority review status to its New Drug Application (NDA) for its gastrointestinal candidate, eluxadoline.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Biointron's RushDATA™: Speeding Up Antibody Discovery

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

First Horizon's $25M Bet: New Center Transforms Houston

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

When to Switch Your LLC to S Corp Status: Tips

Is Your LLC Ready for the S Corp Leap? Thinking about shifting your LLC to S corporation status? You're not alone—many business owners hit this fork in the road as their enterprise starts rolling in more dough. And if you're scratching your head wondering if this switch makes sense for your venture, listen up because timing and context are everything here. When Should...

Will Hair Loss Drugs Challenge Transplant Clinics?

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

SPOC Energy's Hiring Push Signals Growth Surge

A Growing Workforce for a Growing Demand Here we are, smack dab in a bustling week of business news, and among it, SPOC Energy is ramping up its workforce across Alabama. Now, SPOC isn't any run-of-the-mill operation; this Birmingham-based manufacturer messes around with advanced power conversion systems and motor-control automation—a mouthful, sure, but critical stuff...

Foreigner to Rock Irvine with Night Ranger in 2027

Irvine Set for a Rock Revival Talk about a blast from the past! On March 27, 2027, two titans of the rock world, Foreigner and Night Ranger, are set to ignite Irvine like it's the glory days of arena rock all over again. Hosted at the Great Park Live, this show isn't just a concert—it's a full-scale invasion of rock's golden age right into Southern California's heart....

Philip Scroggie's Legacy in Global Energy Projects

A Lifetime of Energy Industry Excellence When you've been around the block in the energy sector as long as Philip D. Scroggie has, you're bound to pick up a few accolades. Recognized as an Inner Circle Lifetime Member, this guy has etched his name in the annals of global energy project management. Yeah, he's been a heavyweight in the oil, gas, and LNG industries, and he's...

TruGreen Finds New Growth in Birch Hill Acquisition

TruGreen's New Chapter Begins In the world of lawn care, TruGreen is sowing the seeds for a revitalized future, courtesy of its recent acquisition by Birch Hill Equity Partners. Based out of Franklin, Tennessee, this powerhouse in the green arena is set to start a fresh chapter, swapping partners like old gloves after a long, 19-year stint with Clayton, Dubilier & Rice...

The Melt Expands with Key Texas Franchise Deal

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

ADI Global Faces Investor Investigation Over Major Write-Down

Towering Goodwill Falls and Investor Scrutiny Well, let's dig into this mess ADI Global Distribution has found itself in. If you were hanging onto ADIG shares, your portfolio probably took quite the hit when they revealed a nasty $659 million goodwill write-down. Imagine opening up those financials and seeing about 62% of goodwill value wiped out overnight. Suddenly, that...